Centre for Sexuality and Health Research and Policy (C-SHaRP), Chennai, India.
The Humsafar Trust, Mumbai, India.
AIDS Behav. 2021 Oct;25(10):3074-3084. doi: 10.1007/s10461-021-03253-5. Epub 2021 Apr 5.
Pre-exposure prophylaxis (PrEP) programs are planned for key populations in India. We examined PrEP awareness and willingness to use PrEP in order to support products and services for MSM. From December 2016 to March 2017, we conducted a survey and discrete choice experiment (DCE)-a technique to quantify the strength of participants' trade-off preferences among various product attributes-to assess willingness to use PrEP and related preferences. MSM were recruited from cruising sites and HIV prevention services in Mumbai and Chennai. DCE data were analyzed using mixed logit regression models and estimated marginal willingness-to-pay, the relative value participants' place on different PrEP attributes. Overall, 76.6% indicated willingness to use PrEP. Efficacy had the greatest effect on choice (high vs. moderate, aOR = 19.9; 95% CI 13.0-30.4), followed by dosing frequency (intermittent vs. daily regimen, aOR = 2.02; 95% CI 1.8-2.2). Participants preferred no (vs. minor) side-effects, subsidized (vs. market) price, and government (vs. private) hospitals. Findings suggest that educational and social marketing interventions should emphasize PrEP's high efficacy and minimal side effects, and programs should provide government-subsidized PrEP with choices of intermittent or daily dosing delivered by government and private hospitals/clinics in order to optimize PrEP uptake among MSM in India.
暴露前预防(PrEP)计划正在印度的重点人群中规划。我们调查了 PrEP 的知晓率和使用意愿,以支持男男性行为者(MSM)的产品和服务。2016 年 12 月至 2017 年 3 月,我们进行了一项调查和离散选择实验(DCE),这是一种量化参与者在各种产品属性之间权衡偏好强度的技术,以评估使用 PrEP 的意愿和相关偏好。MSM 是从孟买和钦奈的 cruising 场所和艾滋病毒预防服务中招募的。使用混合对数回归模型和估计边际意愿支付(参与者对不同 PrEP 属性的相对价值)分析 DCE 数据。总体而言,76.6%的人表示愿意使用 PrEP。疗效对选择的影响最大(高 vs. 中,aOR=19.9;95%CI 13.0-30.4),其次是给药频率(间歇性 vs. 每日方案,aOR=2.02;95%CI 1.8-2.2)。参与者更喜欢没有(vs. 轻微)副作用、补贴(vs. 市场)价格和政府(vs. 私人)医院。研究结果表明,教育和社会营销干预措施应强调 PrEP 的高疗效和最小副作用,并且应提供政府补贴的 PrEP,选择间歇性或每日剂量,由政府和私人医院/诊所提供,以优化印度 MSM 对 PrEP 的接受度。